Logic tells us that if it doesn't add anything to efficacy in combination, then the drug it is used in combination with is superior. In fact, there is no evidence (as seen in this latest trial) that PI-88 does anything to slow the development of lung cancer.
This makes me very worried that the liver cancer "result" is just a statistical anomaly, and the Phase III trial will show that PI-88 is no better than placebo.
If it doesn't work in lung, then I doubt the mechanism is sound for other tissues. Other drugs (such as Nexavar) have shown us this.
Time is clearly running out for PI-88. I don't see any route to profitability, and there is an urgent need to advance their next-generation compound.
PGL Price at posting:
0.0¢ Sentiment: Sell Disclosure: Not Held
